Published in Int J Nanomedicine on March 11, 2015
Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol (1969) 10.33
Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA (2011) 3.57
Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn (2009) 2.35
Electron microscopy of frozen biological suspensions. J Microsc (1983) 1.73
Molecular anatomy of intercellular junctions in brain endothelial and epithelial barriers: electron microscopist's view. Brain Res Brain Res Rev (2003) 1.44
Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol (2008) 1.41
Teratogenic effects of antiepileptic drugs. Lancet Neurol (2012) 1.36
Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure (2009) 1.28
Comparative placental structure. Adv Drug Deliv Rev (1999) 1.17
PSMA-targeted theranostic nanoplex for prostate cancer therapy. ACS Nano (2012) 1.15
Transplacental transport of nanomaterials. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.14
Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials (2011) 1.04
Review: Transport across the placenta of mice and women. Placenta (2012) 1.03
Nanotechnology for delivery of drugs to the brain for epilepsy. Neurotherapeutics (2009) 1.03
Structure of the recombinant alphavirus Western equine encephalitis virus revealed by cryoelectron microscopy. J Virol (2010) 1.03
Placental transport and in vitro effects of Bisphenol A. Reprod Toxicol (2010) 1.02
Recent advances in medicinal chemistry and pharmaceutical technology--strategies for drug delivery to the brain. Curr Top Med Chem (2009) 0.97
Management of epilepsy during pregnancy. Drugs (2007) 0.97
Second-generation antiepileptic drugs and pregnancy: a guide for clinicians. Expert Rev Neurother (2012) 0.97
In vitro models for studying trophoblast transcellular transport. Methods Mol Med (2006) 0.96
Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Release (2004) 0.94
Modeling placental transport: correlation of in vitro BeWo cell permeability and ex vivo human placental perfusion. Toxicol In Vitro (2009) 0.92
Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol (2014) 0.92
Antiepileptic drugs and pregnancy outcomes. Am J Med Genet A (2012) 0.92
Controlling drug delivery across the placenta. Eur J Pharm Sci (1999) 0.91
Techniques to study human placental transport. Adv Drug Deliv Rev (1999) 0.91
In utero oxcarbazepine and a withdrawal syndrome, anomalies, and hyponatremia. Pediatr Neurol (2013) 0.90
In vitro targeting and imaging the translocator protein TSPO 18-kDa through G(4)-PAMAM-FITC labeled dendrimer. J Control Release (2013) 0.89
In vitro placental model optimization for nanoparticle transport studies. Int J Nanomedicine (2012) 0.88
Preparation of nanoparticles by solvent displacement for drug delivery: a shift in the "ouzo region" upon drug loading. Eur J Pharm Sci (2010) 0.86
Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand (1993) 0.85
Internal benchmarking of a human blood-brain barrier cell model for screening of nanoparticle uptake and transcytosis. Eur J Pharm Biopharm (2011) 0.85
Colloidal gold modified with a genetically engineered nitroreductase: toward a novel enzyme delivery system for cancer prodrug therapy. Langmuir (2011) 0.83
Preparation, characterization, and transport of dexamethasone-loaded polymeric nanoparticles across a human placental in vitro model. Int J Pharm (2013) 0.81
Targeting caspase-3 as dual therapeutic benefits by RNAi facilitating brain-targeted nanoparticles in a rat model of Parkinson's disease. PLoS One (2013) 0.80
[Epilepsy and pregnancy. Balancing between risks to the mother and child]. Lakartidningen (1997) 0.80
Transplacental passage of oxcarbazepine and its metabolites in vivo. Epilepsia (2001) 0.80